SCALE prediabetes progression trial
In a randomised trial of adults with prediabetes and obesity, subcutaneous liraglutide was superior to placebo at preventing progression to type 2 diabetes over approximately 3 years, following an initial 56-week weight-focused trial phase (SCALE Obesity and Prediabetes).
- Study type
- Human trial
- Population
- Adults with obesity and prediabetes.
- Source
- 1 le Roux et al., 2017
Limitation: Sponsor-funded (Novo Nordisk).
Limitations in full
Sponsor-funded (Novo Nordisk). In the 160-week trial, 2% of the liraglutide group and 6% of the placebo group were diagnosed with diabetes; about half of participants completed the trial.